Talis Biomedical Corp expected to post a loss of 73 cents a share - Earnings Preview

Talis Biomedical

10/05/2023 03:03

* Talis Biomedical Corp  TLIS.OQ   TLIS.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 11. 
    * The Redwood City California-based  company is expected to
report
 a 71.4% decrease in revenue to $250 thousand from $874 thousand
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Talis Biomedical
Corp is
for a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Talis
Biomedical
Corp is $0.35​, below​ its last closing price of $0.54. ​​​

This summary was machine generated May 10 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated